Germline and Somatic Genomic Testing for Metastatic Prostate Cancer
International Urology Cancer Summit shared on LinkedIn:
” Here latest ASCO Clinical Practice Guideline:
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer
This guideline highlights the critical role of germline and somatic DNA sequencing in shaping treatment strategies, identifying actionable mutations, and guiding cascade testing for families. It’s a significant step forward in precision oncology, addressing not only therapeutic implications but also prognostic factors and family risk management.
Key recommendations include:
- Universal germline testing for all patients with metastatic prostate cancer.
- Somatic testing to identify actionable mutations and guide targeted therapies like PARP inhibitors.
- Consideration of ctDNA and repeat testing in specific scenarios to address evolving tumor biology.
Explore the full guideline
Authors: Evan Y. Yu, R. Bryan Rumble, Neeraj Agarwal, Heather H. Cheng, Scott E. Eggener, Rhonda L. Bitting, Himisha Beltran, Veda N. Giri, Daniel Spratt, Brandon Mahal, Kevin Lu, Tony Crispino, and Edouard J. Trabulsi
A special thanks to the incredible team behind this work:
Evan Y. Yu,
R. Bryan Rumble,
Neeraj Agarwal,
Himisha Beltran,
Heather H. Cheng,
Scott E. Eggener,
Veda N. Giri,
Daniel Spratt,
Rhonda L. Bitting,
Brandon Mahal,
Tony Crispino,
Edouard J. Trabulsi. “
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023